SCHEMBL6440840

SCHEMBL6440840

N#Cc1c(NCc2ccccc2Cl)nc(N)nc1-n1cccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.45
PDE5A O76074 1/20 0.40
HRH4 Q9H3N8 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
NLRP3 Q96P20 3/20 0.39
ALDH1A1 P00352 3/20 0.39
GAA P10253 3/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 3/20 0.38
PDGFRB P09619 1/20 0.38
KDR P35968 1/20 0.38
PDE2A O00408 1/20 0.38
KCNN3 Q9UGI6 1/20 0.36
CHUK O15111 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443563 0.88 ADORA2A (0.45) ADORA2AHRH4HRH3NLRP3ALDH1A1
SCHEMBL6443235 0.86 ADORA2A (0.49) ADORA2ANLRP3ALDH1A1GAAMAPT
SCHEMBL6443539 0.81 ADORA2A (0.48) ADORA2ANLRP3ALDH1A1KDM4ECHUK
SCHEMBL6441943 0.80 ADORA2A (0.46) ADORA2ANLRP3CHUK
SCHEMBL6440882 0.79 ADORA2A (0.42) ADORA2ANLRP3ALDH1A1MAPTLMNA
SCHEMBL6446164 0.78 ADORA2A (0.43) ADORA2ANLRP3ALDH1A1GAAMAPT
SCHEMBL6449459 0.78 APP (0.52) ADORA2AHRH4NLRP3ALDH1A1GAA
SCHEMBL6443232 0.77 ADORA2A (0.42) ADORA2ANLRP3ALDH1A1MAPTLMNA
SCHEMBL6442124 0.77 P2RX3 (0.41) ADORA2ANLRP3GAAMAPTLMNA
SCHEMBL6442325 0.74 NLRP3 (0.42) ADORA2ANLRP3ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885PDE5A 637/4885HRH4 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.